Mitochondria and Mitochondrial Cascades in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 153 of the 154 references it cites were found in a registry or an index.
Abstract
Decades of research indicate mitochondria from Alzheimer’s disease (AD) patients differ from those of non-AD individuals. Initial studies revealed structural differences, and subsequent studies showed functional deficits. Observations of structure and function changes prompted investigators to consider the consequences, significance, and causes of AD-related mitochondrial dysfunction. Currently, extensive research argues mitochondria may mediate, drive, or contribute to a variety of AD pathologies. The perceived significance of these mitochondrial changes continues to grow, and many currently believe AD mitochondrial dysfunction represents a reasonable therapeutic target. Debate continues over the origin of AD mitochondrial changes. Some argue amyloid-β (Aβ) induces AD mitochondrial dysfunction, a view that does not challenge the amyloid cascade hypothesis and that may in fact help explain that hypothesis. Alternatively, data indicate mitochondrial dysfunction exists independent of Aβ, potentially lies upstream of Aβ deposition, and suggest a primary mitochondrial cascade hypothesis that assumes mitochondrial pathology hierarchically supersedes Aβ pathology. Mitochondria, therefore, appear at least to mediate or possibly even initiate pathologic molecular cascades in AD. This review considers studies and data that inform this area of AD research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondria, too, are damaged by oxidative and nitrosative stress in AD as noted [34].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The presence of Aβ oligomers in mitochondrial membranes is consistent with Aβ-induced mitochondrial dysfunction occurring early in the disease progression timeline [34,53].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondrial dysfunction plays a fundamental role in AD pathogenesis2 and represents an early event2.”
From Altered mitochondrial dynamics and function in APOE4-expressing astrocytes (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondrial dysfunction plays a fundamental role in AD pathogenesis2 and represents an early event2.”
From Altered mitochondrial dynamics and function in APOE4-expressing astrocytes (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Oxidative stress from mitochondrial dysfunction and reactive oxygen species (ROS) accumulation further heightens neuronal vulnerability [6].”
From What Are the Key Biological Pathways Through Which Lifestyle Factors Influence Neurodegeneration? (2025) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Davis, R. E., Miller, S., Herrnstadt, C., Ghosh, S. S., Fahy, E., Shinobu, L. A., Galasko, D., Thal, L. J., Beal, M. F., Howell, N., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4526 · Cited by 341
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“Based on assumptions made by the amyloid cascade hypothesis, first proposed in the early 1990 s [22, 23], the latter possibility seemed more likely.”
BackgroundSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 1×
“plaques may arguably have AD; a current construct refers to this state as “preclinical AD” [144].”
BackgroundHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Premature ageing in mice expressing defective mitochondrial DNA polymerase
Trifunovic, A., Wredenberg, A., Falkenberg, M., Spelbrink, J. N., Rovio, A. T., Bruder, C. E., Bohlooly-Y, M., Gidlöf, S., Oldfors, A., Wibom, R., et al. (2004) · Nature · doi:10.1038/nature02517 · Cited by 2,734 · cited 1×
“Due to the presence of the mutated mtPOLG transgene, these mice acquire excess somatic mtDNA mutations and mitochondrial dysfunction [65, 66].”
BackgroundAmyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“Based on assumptions made by the amyloid cascade hypothesis, first proposed in the early 1990 s [22, 23], the latter possibility seemed more likely.”
BackgroundBloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194 · cited 1×
“In response to this, some now speculate A itself is insufficient to cause the disease, but instead initiates AD by triggering a critical change in tau biology [114, 119, 120].”
Background
Research works printed but not linked: 1
- Parker WD (1990) Sporadic neurologic disease and the electron transport chain: A hyothesis In Proceedings of the 1989 Scientific Meeting of the American Society for Neurological Investigation: New Developments in Neuromuscular Disease, Pascuzzi RM, ed. Indiana University Printing Services, Bloomington, Indiana.
Cited by
Items 701–800 of 856
Klinman, E., Kwon, J., Dolle, R. E., Pak, S. C., Silverman, G. A., Perlmutter, D. H., & Yoo, A. S. J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.02.680077 · Cited by 1
“…been linked to the pathogenesis of aging and are tied to the pathologic changes associated with neurodegenerative conditions such as Alzheimer disease (Fang et al. , 2019; Chakravorty, Jetto and Manjithaya, 2019; Birnbaum et al. , 2018; Swerdlow, 2018; Nixon et al. , 2005; Lipinski et al. , 2010).”
Progranulin loss induces mitochondrial dysfunction and ferroptosis in human cerebral organoidsPreprint
Camargo, C. M., Almeida, M. C., Mejía‐Cupajita, B., Hwang, I., Faynus, M. A., Carrettiero, D. C., & Kosik, K. S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.11.29.691344 · Cited by 1
“Oxidative damage to lipids can lead to the formation of lipofuscin, a hallmark of NCL and a phenomenon also observed in PGRN haploinsufficiency (Ward et al., 2017) and other neurodegenerative disorders such as Huntington's disease, AD and PD (50).”
InfluentialNsangou, Y. A. N., Wörheide, M. A., Seyfried, N. T., Dönitz, J., Kaddurah‐Daouk, R., Kastenmüller, G., & Arnold, M. (2026) · medRxiv · doi:10.64898/2026.02.18.26346567 · Cited by 1
Gabal, E., Nguyen, T. K. O., Kovalenko, T., Gao, H., Rappaport, N., Funk, C. C., Baloni, P., & Trushina, E. V. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.14.732179 · Cited by 1
“These findings are consistent with the mitochondrial cascade hypothesis, which proposes that inherited and acquired deficits in mitochondrial function act upstream of classical AD pathology and drive progressive network failure 12 .”
What Are the Key Biological Pathways Through Which Lifestyle Factors Influence Neurodegeneration?
Su, Z. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2025.au25765
Lee, J.-S., Park, E., & Kim, I.-S. (2018) · Journal of Experimental & Biomedical Sciences/Biomedical Science Letters · doi:10.15616/bsl.2018.24.2.130
“Brief Communication - 131 - 은 직접적으로 또는 간접적으로 증가된 세포질 칼슘 농 도를 유도하는 산화 스트레스로 인한 미토콘드리아 기능 장애로 나타난다(Swerdlow, 2017).”
The interplay between mitochondria-endoplasmic reticulum contacts and Alzheimer’s disease
Leal, N. S., & João, N. (2019) · Figshare · Cited by 1
Uncovering temporally sensitive targeting motifs for traumatic brain injury via phage displayPreprint
Martinez, B. I., Mousa, G. A., Fleck, K., MacCulloch, T., Diehnelt, C. W., Stephanopoulos, N., & Stabenfeldt, S. E. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.16.155325
“For example, mitochondrial dysfunction is a critical earlyoccurring factor that influences apoptosis and reactive oxygen species overproduction in both Alzheimer’s patients and animal models [66, 67].”
BackgroundMuthuraman, A., Ramesh, M., & Kumar, T. V. R. (2020) · Springer eBooks · doi:10.1007/978-981-15-5167-3_6
Huang, Y. H., Jia, H., & Bao, W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816475-4.00013-6 · Cited by 1
Goshadrou, F., Yekta, R. F., Oskouie, A. A., & Eslami, M. (2021) · کومش · doi:10.29252/koomesh.23.1.105
The Interplay of Progestins, Matrix Metalloproteinases, and the Aging Brain
Porter, K. N. (2020) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.7973
Singulani, M. P. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2020.tde-23122020-202326
Guha, S. K., Cheng, A., Carroll, T., King, D. P., Koren, S. A., Swords, S., Nehrke, K. W., & Johnson, G. V. W. (2021) · Research Square · doi:10.21203/rs.3.rs-1096882/v1
A novel sight of the primary active compounds from Umbelliferae: focusing on mitochondria
Yang, L., Ni, N., Hong, Y., & Shen, L. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-021-02822-6 · Cited by 1
Хилажева, Е. Д., Mosiagina, A. I., Morgun, A. V., Malinovskaya, N. A., Gorina, Y. V., Kharitonova, E. V., Lopatina, O. L., & Salmina, A. B. (2022) · Cell and Tissue Biology · doi:10.1134/s1990519x22020067 · Cited by 1
“It has been shown that mitochondrial dysfunction can also be a trigger or a concomitant mechanism in the development of AD (Swerdlow, 2018).”
BackgroundSong, H. (2019) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/70032
Smit, C., de Wet, S., van Blerk, T. B., & Loos, B. (2023) · Biogerontology · doi:10.1007/s10522-022-10012-z
“(1234567890) in the generation of ROS, and through affecting the localization of additional mitochondrial proteins (Wang et al. 2014; Pajares et al. 2018; Swerdlow 2018).”
BackgroundAlzheimer’s Disease and COVID-19 Pathogenic Overlap: Implications for Drug Repurposing
Golzari-Sorkheh, M., Liyanage, S. I., Reed, M. A., & Weaver, D. F. (2023) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2023.39 · Cited by 1
“32 Some data suggest mitochondrial dysfunction temporally occurs upstream from proteopa-thies, indicating a primary mitochondrial pathology may supersede amyloid and tau pathologies; other data suggest that mitochondrial dysfunction is a consequence of amyloid proteop-athy but nonetheless…”
BackgroundNg, E. L., Reed, A. L., O’Connell, C. B., & Alder, N. N. (2023) · doi:10.3791/65561-v
Targeting Various Pathogenic Pathways for the Development of Anti-alzheimer’s Drugs: An Update
Ambreen, S., Fatima, N., Umar, M., Shaququzzaman, M., Alam, M. M., & Ali, R. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266274924231002110733
Kerr, N. R. (2023) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/97056
Boeddrich, A., Haenig, C., Neuendorf, N., Blanc, E., Ivanov, A., Kirchner, M., Schleumann, P., Bayraktaroğlu, I., Richter, M., Molenda, C., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23714235
de Dios, C., Abadin, X., Agujetas, V. R., Jiménez-Martínez, M., Morales, A., Trullás, R., Marí, M., & Colell, A. (2023) · Figshare · doi:10.6084/m9.figshare.22626457
Rafaish, H. G., Albazi, W. J., Al-Aameli, M. H., AL-Thuwaini, T. M., & Jhoni, G. H. (2024) · Journal of Kerbala for Agricultural Sciences · doi:10.59658/jkas.v11i2.1842
Acker, H., Ehleben, W., & Horschig, R. N. J. M. (2024) · Research Square · doi:10.21203/rs.3.rs-4764825/v1
Wu, X., Chen, H., Ge, Z., Luo, B., Pan, H., Shen, Y., Xie, Z., & Zhou, C. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1397281
“…closely related to many human diseases, such as cancer, neurodegenerative diseases [Parkinson’s disease (Macdonald et al., 2018), Alzheimer’s disease (Swerdlow, 2018), and Huntington’s disease (Jodeiri Farshbaf and Ghaedi, 2017)], and myopathy (Kim, 2017; Xie et al., 2020; Andrieux et al., 2021).”
BackgroundNeurological diseases and pathophysiology
Sonkaya, R., & Malikov, E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18858-9.00017-2
The genetic basis of neurodegenerative disorders: Implications in Alzheimer's disease
Jilani, M. G., Hoque, M., Tabrez, S. S. M., & Ali, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15540-6.00002-1 · Cited by 1
Associations Between Walking Pace, APOE-ε4 Genotype, and Brain Health in Middle-Aged to Older Adults
Aslan, D. H., Sayre, M. K., Bharadwaj, P. K., Ally, M., Maltagliati, S., Lai, M. H. C., Wilcox, R. R., Klimentidis, Y. C., Alexander, G. E., & Raichlen, D. A. (2025) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000003646
Acharya, D., Butters, E., Caicedo, A., Su, L., O'Brien, J. T., & Bale, G. M. (2025) · Journal of Biomedical Optics · doi:10.1101/2025.02.20.639231 · Cited by 3
Mitochondrial Bioenergetics in Different Pathophysiological Conditions 4.0
Valenti, D., & Atlante, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073396
Kshirsagar, S., Deshmukh, H., Reddy, A. P., Reddy, A. P., & Reddy, P. H. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251334666 · Cited by 1
“6 This capacity to modulate oxidative stress highlights grounding ’ s potential as a neuroprotective strategy, particularly given that oxidative damage is a key driver of AD progression.”
InfluentialLee, Y.-S., Seo, Y.-L., Song, G. J., Cho, K. S., Yoo, Y. K., & Cheong, H. (2025) · Research Square · doi:10.21203/rs.3.rs-6546219/v1 · Cited by 1
Hernández, A. M., & Aldasoro, M. (2025) · doi:10.60096/fundacionavanza/2002025
Metabolic disorders associated with mitochondrial dysfunction
Akash, M. S. H., & Rehman, K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-36312-2.00011-5 · Cited by 1
Integrative Approach Towards Treatment of Alzheimer's and Other Dementias
Khan, N. A., Sambyal, N., Tanzeelah, Sachdeva, P., Siwan, D., Rehman, A., Dey, A., Ghosh, S., Mahajan, A. A., Rizvi, S., et al. (2025) · Wiley eBooks · doi:10.1002/9781394336807.ch8
The Main Mechanisms of Development of Cognitive Impairment
Bogolepova, A. N. (2025) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-025-01877-x
“Impaired energy metabolism invariably precedes the clinical onset of AD, and mitochondrial dysfunction has been established as an early and signi fi cant feature of the disease [15].”
Okhalnikov, A. D., Anastasia, M., Ermoshina, A. A., & Maria, G. B. (2025) · International Conference Neurotechnologies and Neurointerfaces (CNN) · doi:10.1109/cnn67635.2025.11177480
“Recent studies have revealed disruptions in mitochondrial dynamics as well as a reduction in normal mitochondria in AD, which manifest at early stages of the disease [7].”
Small molecular therapeutic targets for neurodegenerative diseases
Rangappa, N., Upadhyay, R., Lakshman, N., Ramasamy, S., Sevanan, M., Justin, A., & Chinnathambi, S. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.10.012
Introduction to age-related cognitive-behavioural changes
Broderick, M.-Z. L., Taji, H., Hajj, F., Balakumar, B., Al-Achkar, O., & Tasnim, D. (2025) · Progress in brain research · doi:10.1016/bs.pbr.2025.08.019 · Cited by 1
Protein Misfolding and Aggregation in the Pathogenesis of Alzheimer’s Disease
Kim, J., & Kim, H. (2025) · Gyemyeong uidae haksulji · doi:10.46308/kmj.2025.00164
“Elevated ROS further cause DNA damage, protein oxidation, and lipid peroxidation, ultimately activating apoptotic pathways [78].”
Guha, S. K., Fischer, S., Johnson, G. V. W., & Nehrke, K. (2020) · Figshare · doi:10.6084/m9.figshare.13212863
Terada, T., Therriault, J., Kang, M. S. P., Savard, M., Pascoal, T. A., Lussier, F. Z., Tissot, C., Wang, Y.-T., Benedet, A. L., Matsudaira, T., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14490235
Guha, S. K., Fischer, S., Johnson, G. V. W., & Nehrke, K. W. (2020) · Figshare · doi:10.6084/m9.figshare.13212866
Wu, C., Yang, L., Feng, S., Zhu, L., Yang, L., Liu, T. C., & Duan, R. (2022) · Figshare · doi:10.6084/m9.figshare.21259535
Boeddrich, A., Haenig, C., Neuendorf, N., Blanc, E., Ivanov, A., Kirchner, M., Schleumann, P., Bayraktaroğlu, I., Richter, M., Molenda, C., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23714229
Boeddrich, A., Haenig, C., Neuendorf, N., Blanc, E., Ivanov, A., Kirchner, M., Schleumann, P., Bayraktaroğlu, I., Richter, M., Molenda, C., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23714232
Chen, X.-Q., Das, U., Park, G., & Mobley, W. C. (2021) · Figshare · doi:10.6084/m9.figshare.14196547
Guha, S. K., Fischer, S., Johnson, G. V. W., & Nehrke, K. (2020) · Figshare · doi:10.6084/m9.figshare.13212857
Stepanov, Y. V., Golovynska, I., Zhang, R., Golovynskyi, S., Stepanova, L. I., Gorbach, O. I., Dovbynchuk, T., Garmanchuk, L., Ohulchanskyy, T. Y., & Qu, J. (2022) · Figshare · doi:10.6084/m9.figshare.20098663
Guha, S. K., Fischer, S., Johnson, G. V. W., & Nehrke, K. (2020) · Figshare · doi:10.6084/m9.figshare.13212854
Silva, D. F., Candeias, E., Esteves, A. R., Magalhães, J. D., Ferreira, I. L., Nunes‐Costa, D., Rego, A. C., Empadinhas, N., & Cardoso, S. M. (2020) · Figshare · doi:10.6084/m9.figshare.13199281
de Dios, C., Abadin, X., Agujetas, V. R., Jiménez-Martínez, M., Morales, A., Trullás, R., Mari, M., & Colell, A. (2023) · Figshare · doi:10.6084/m9.figshare.22626454
Guha, S. K., Fischer, S., Johnson, G. V. W., & Nehrke, K. (2020) · Figshare · doi:10.6084/m9.figshare.13212860
Ning, Z., Liu, Y., Wan, M., Zuo, Y., Chen, S., Shi, Z., Xu, Y., Li, H., Ko, H., Zhang, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26733199
Guha, S. K., Fischer, S., Johnson, G. V. W., & Nehrke, K. W. (2020) · Figshare · doi:10.6084/m9.figshare.13212851
Ning, Z., Liu, Y., Wan, M., Zuo, Y., Chen, S., Shi, Z., Xu, Y., Li, H., Ko, H., Zhang, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26733196
Acharya, D., Butters, E., Caicedo, A., Su, L., O’Brien, J., & Bale, G. M. (2025) · European Conferences on Biomedical Optics (ECBO) · doi:10.1364/ecbo.2025.w1a.2
Medicinal Mushrooms as an Effective Early Nutritional Intervention for Dementia Management
Gautam, G., & Kaur, J. (2025) · Nutritional neurosciences · doi:10.1007/978-981-95-2774-8_10
Daynes, S., & Pickett, B. E. (2025) · medRxiv · doi:10.64898/2025.12.01.25341417
Finney, C. A., An, L., Winchester, L. M., Vogel, J., Wilkins, H. M., Burns, J. M., Swerdlow, R. H., Slawson, C. M., Rothstein, J. D., Lutz, M. W., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.09.693329 · Cited by 1
Self-citationAcharya, D., Butters, E., Caicedo, A., Su, L., O’Brien, J., & Bale, G. M. (2025) · Translational Biophotonics: Diagnostics and Therapeutics · doi:10.1117/12.3097858
“Although the relationship between oxCCO concentration and AD pathology may not be linear, studies suggest that amyloid − β protein precursors are known to block mitochondrial CCO [3].”
Fu, H., Li, J., Zhang, C., Gao, G., Ge, Q., & Daxiang, C. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.30.696965
Mitokondriyal Disfonksiyonun Yaşlanmadaki Rolü
Kömüroğlü, A. U. (2025) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub1069.c4207
MITOCHONDRIAL DYSFUNCTION IN DISEASE: PATHOGENIC MECHANISMS AND NOVEL THERAPIES
Wycik, M., Chmielewski, H., Komar, J., Wądołowski, A., Kondratiuk, G., Kondrat, A., Szczupak, M., Mierzejewski, P., Werno, J., & Twarowska, Z. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4424
Elesclomol Diminishes Redox Imbalance in Peripheral Tissues of Mblac1 Knockout Mice
Neghabi, M., Nategh, P., Stauffer, A. M., Hahn, M. K., Blakely, R., & Ranji, M. (2026) · Journal of Biophotonics · doi:10.1002/jbio.70224
“A better understanding of the relationships be-tween AD and its metabolic perturbations may provide insights into AD disease mechanisms and AD comorbidities beyond the brain [7, 8].”
Wang, E. J., Oğuztüzün, Ç., Xu, R., & Gao, Z. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261415635 · Cited by 1
Crosstalk in Alzheimer’s-delirium nexus: Molecular mechanisms and therapeutic repurposing
Iqbal, S., & Shen, B. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.01.004
Haikun Shenxi Capsule alleviates Alzheimer's disease by targeting mitophagy to clear turbidity toxin
He, S., Fu, X.-J., Sun, Y.-H., Zhou, P., Zhang, S., & Wang, Z. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121367
Saeed, S., Khan, S., Noor, A., Zerr, I., & Zafar, S. (2026) · Molecular Informatics · doi:10.1002/minf.70024 · Cited by 1
Hallucinogenic Therapy in Alzheimer’s Disease targeting Mitochondria-Associated Membranes
Minauro‐Sanmiguel, F., & Vargas-Pérez, H. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.02.028
Zhou, Z., Zhang, W., Zhai, Z., Kong, F., Zhao, Y., Xu, Y., & Sun, T. (2026) · European journal of medical research · doi:10.1186/s40001-026-04057-w
Bientinesi, E., Vignoli, A., Ristori, S., Salobehaj, M., Bertoni, G., Monti, D., & Tenori, L. (2026) · Metabolites · doi:10.3390/metabo16030173
“…certain alterations, such as phosphocreatine depletion, were confined to the intracellular compartment suggests a direct impairment of energy-buffering mechanisms that is not immediately mirrored in the extracellular compartment, consistent with astrocytic mitochondrial stress responses [24,32].”
Molecular mechanism of Alzheimer’s disease using integrated multi-omics
Alhusaini, M., Mussa, B. M., İlçe, B. Y., Alhaj, H. A., & Hamoudi, R. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1735696
“Meanwhile, neurons exposed to this inflammatory milieu experience mitochondrial dysfunction, oxidative stress, and impaired nutrient utilization, hallmarks of metabolic failure observed in AD (Isaac, 2016; Swerdlow, 2017).”
Yang, L., Song, G., Parker, E., & Yang, L. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05832-w
Santerre, M., Allen, C. N. S., Arjona, S. P., Shcherbik, N., & Sawaya, B. E. (2026) · AIDS · doi:10.1097/qad.0000000000004507
Raajasekar, S. (2026) · Research Square · doi:10.21203/rs.3.rs-9252110/v1
Lefèvre‐Arbogast, S. (2019) · theses.fr (ABES) · doi:10.70675/6915e632z663fz4caaz9c7az455ad25755da
Implication du fragment C99 dans l’avènement des phénotypes pathologiques de la maladie d’Alzheimer
Bourgeois, A. (2019) · theses.fr (ABES) · doi:10.70675/bb8ccf34zec6cz4bb6z82b4z3030b9cb28f7
Valverde, A. (2020) · theses.fr (ABES) · doi:10.70675/f1b70734zf4e3z4870z8fbdz950d831642a7
Sayehmiri, F., Parvenous, M., Vakili, K. G., Ebrahimi, R., Batool, Z., Bazgir, N., Kazemi, K., Moafi, M., Ebrahimi, M. J., & Hajiesmaeili, M. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01809-9
A multimodal AI model for modeling the genetic risk factor of Alzheimer’s diseasePreprint
Nguyen, T., Woods, C., Liu, J., Wang, C., Lin, A., & Cheng, J. (2026) · medRxiv · doi:10.64898/2026.04.13.26350803
Pathophysiology and Molecular Mechanisms of Alzheimer’s Disease
Chandragiri, S. S., Mathur, M., & Mathur, N. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814953126010005
Li, Y.-P., Gong, J., Yang, L., Peng, R.-R., Jin, L., wang, F., Zhao, X., & Wang, L. (2026) · Research Square · doi:10.21203/rs.3.rs-9230899/v1
Kumar, S. V., Malviya, R., Chandra, P., Sridhar, S. B., Shareef, J., Wadhwa, T., & Balusamy, B. (2026) · Results in Chemistry · doi:10.1016/j.rechem.2026.103355
Tan, M., Zeng, J., Zhou, H., Yang, S., Wang, T., Zhong, M., 王彤宇, Liu, Z., Dai, Y., & Song, S. (2026) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2026.1829278
“In older brains, mitochondrial reserve is already reduced (Sun et al., 2016; Swerdlow, 2018).”
Podder, A., Liew, Y. J., Cary, G. A., Carter, G. W., & Uyar, A. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70264
“44 These results highlight how individualized functional profiling can inform both pathogenic and resilience-related mechanisms across preclinical and symptomatic stages.”
Mishra, T., Sharma, S., Joshi, S., Prajapati, S. K., & Tejaswi (2025) · Neurophysiology · doi:10.1007/s11062-026-10002-8
“A vicious cycle of metabolic dysfunction is created when the synthesis of essential proteins in the ETC is impaired due to the oxidative damage to the mitochondrial DNA [27, 28].”
Investigation of Neurotransplantation and Regenerative Therapy in Preclinical Models
Sugaya, K. (2026) · Contemporary clinical neuroscience · doi:10.1007/978-3-032-18296-8_28
Salihoğlu, R., Can, Ş., Dandekar, T., & Bencúrová, E. (2026) · Computational and Structural Biotechnology Journal · doi:10.34133/csbj.0134 · Cited by 1
“SLC25A46, implicated in cristae organization, is compatible with mitochondrial maintenance hypotheses in aging and failure modes in AD [ 53 ].”
Metabolic dysregulation in Alzheimer’s disease: Mechanisms, markers, and therapeutic prospects
Mittal, R., Priya, Banerjee, J., & Dixit, A. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.05.011
Mitochondrial dysfunction in Alzheimer’s disease: connecting pathophysiology with neuroimaging
Hu, J., Lai, J., Zhang, B., Jiang, X., Ma, H. F., & Liu, Y. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1748227
“This review systematically elucidates the multidimensional mechanisms of mitochondrial dysfunction in AD and its interactions with A β and tau pathology (Picard and Shirihai, 2022; Swerdlow, 2018).”
InfluentialPlasma Proteomic Networks Reveal Shared Biology with Brain Linked to Alzheimer’s Disease PathologyPreprint
GUO, Q., Ping, L., Rathore, S., Duong, D. M., Shantaraman, A., Fox, E. J., Johnson, E. C. B., Lah, J. J., Levey, A. I., & Seyfried, N. T. (2026) · medRxiv · doi:10.64898/2026.05.26.26353866
Kaikini, A. A., Shi, A., Francis, P. T., Swerdlow, R. H., Troakes, C., Kennedy, J., Hodgkinson, A., & Malik, A. N. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.03.729204
“…diabetes and AD are distinct diseases, they share intersecting biological processes, including chronic inflammation, oxidative stress and impaired insulin signalling in both the periphery and the brain, and mitochondrial dysfunction, which may converge to influence neurodegeneration 6,7,29 .”
Self-citationAdvances in neurotherapeutics for neurodegeneration
Kapur, D., Vashisht, D., & Singh, T. (2026) · Discover Neuroscience · doi:10.1186/s13064-026-00279-0
“…(Aβ) and Aβ precursor protein (APP) accumulation disrupts mitochondrial physiology by interacting with mitochondrial complexes, reducing cytochrome oxidase activity, and most importantly disrupts intra-cellular calcium homeostasis, thereby promoting neuronal hyperexcitability and dysfunction [119].”
Gogoi, H., & Dey, P. (2026) · Pharmacological Research - Natural Products · doi:10.1016/j.prenap.2026.100795
Metadata
- Authors
- Swerdlow, R. H.
- Affiliations
- University of Kansas (US)
- Corresponding author
- Swerdlow, Russell H.
- ORCID
- Swerdlow, Russell H.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2017-10-07
- Volume
- 62
- Issue
- 3
- Pages
- 1403-1416
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC5869994
- OpenAlex
- W2764071986
- Cited by
- 850
- References
- 154
- Citations by year
- 2026: 126 · 2025: 106 · 2024: 97 · 2023: 110 · 2022: 122 · 2021: 114 · 2020: 106 · 2019: 49 · 2018: 18 · 2017: 1
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P30AG035982)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, mitochondrial dysfunction
- MeSH terms
- Alzheimer Disease, Animals, Humans, Mitochondria
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.